COPD and Asthma Therapeutics Market Size & Growth Forecast 2027–2036, By Segments (Drug Class, Indication, Device/Product, Distribution Channel, Technology/Software), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Drug Class Segment Analysis: Anti-IgE and Anti-IL Monoclonal Antibodies (Largest & Fastest-Growing Segment)

The anti-IgE and anti-IL monoclonal antibodies segment accounted for the largest market share of 24.54% in 2026 and is also expected to register the fastest growth in the COPD and asthma therapeutics market, supported by the increasing use of targeted biologic therapies for patients with severe or difficult-to-control respiratory disease. These therapies are designed to address specific immune pathways involved in airway inflammation, enabling more targeted management than conventional broad-acting treatments. Growing recognition of different inflammatory phenotypes in asthma is encouraging clinicians to consider biologic therapies for patients who remain inadequately controlled with standard approaches. Continued advances in understanding immune-mediated respiratory conditions are also supporting the development and adoption of therapies directed at specific inflammatory mechanisms. The ability of anti-IgE and anti-IL therapies to provide targeted treatment options for appropriate patient populations is strengthening their clinical relevance. As diagnosis improves and treatment strategies increasingly emphasize personalized approaches, demand for these monoclonal antibody therapies is expected to expand.

Indication Segment Analysis: Asthma (Largest Segment) vs COPD (Fastest-Growing Segment)

The asthma segment represents the largest indication segment in the COPD and asthma therapeutics market, reflecting the substantial demand for treatments aimed at controlling chronic airway inflammation, bronchoconstriction, and recurring respiratory symptoms. Asthma management requires long-term therapeutic strategies that can reduce symptom severity, prevent exacerbations, and improve respiratory function across different patient populations. Increasing disease awareness and improvements in diagnosis are supporting treatment uptake, while the growing recognition of severe and uncontrolled asthma is creating demand for advanced therapeutic options. The availability of multiple treatment approaches, ranging from conventional inhaled therapies to targeted biologics, enables treatment to be adapted according to disease severity and patient characteristics. Greater emphasis on disease control and prevention of acute exacerbations is further supporting continued demand for asthma therapeutics.

The COPD segment is expected to grow at the fastest pace, driven by the persistent burden of chronic respiratory disease and the need for therapies that can improve symptom management and reduce exacerbations. COPD is associated with progressive limitations in airflow and can significantly affect daily functioning, creating an ongoing need for effective pharmacological management. Increasing awareness of early diagnosis and disease management is encouraging more patients to seek treatment, while improvements in therapeutic approaches are expanding options for different stages and characteristics of the disease. The growing focus on preventing exacerbations and slowing the impact of disease progression is also supporting demand for advanced COPD treatments. As healthcare systems place greater emphasis on improving long-term respiratory outcomes and managing the broader burden associated with COPD, the demand for effective therapeutics is expected to increase.

Device/Product Segment Analysis: Inhalers (Largest Segment) vs Nebulizers (Fastest-Growing Segment)

The inhalers segment represents the largest device/product segment in the COPD and asthma therapeutics market, supported by their widespread use for delivering respiratory medicines directly to the airways. Inhalers provide a convenient method of administering medications and are available across a broad range of therapeutic categories used for long-term disease management and symptom control. Their portability and suitability for routine use make them an important component of respiratory treatment, particularly for patients requiring regular medication administration. Improvements in inhaler design, dose delivery, usability, and formulations containing multiple medications are further supporting their continued adoption. Increasing emphasis on adherence and effective self-management is also encouraging the development of devices that are easier for patients to use correctly. As inhaled therapies remain central to the management of chronic respiratory conditions, inhalers are expected to maintain a strong position in the device/product segment.

The nebulizers segment is expected to grow at the fastest pace, driven by their ability to deliver aerosolized medication over a sustained period and their relevance for patients who experience difficulty using conventional inhaler devices. Nebulizers can be particularly useful in settings where controlled medication delivery is required or where patients have limitations affecting inhaler technique. Their application across different patient groups and treatment environments is supporting broader utilization, while improvements in device portability, ease of operation, and treatment efficiency are increasing their practicality. Growing attention to patient-specific treatment approaches is also encouraging healthcare providers to consider delivery devices according to individual needs and capabilities. As respiratory disease management becomes increasingly focused on effective medication delivery and patient adherence, demand for advanced nebulization devices is expected to expand.